Yang, Y., MacLeod, V., Dai, Y., Khotskaya-Sample, Y., Shriver, Z., Venkataraman, G., . . . Sanderson, R. D. (2007). The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy. American Society of Hematology.
Chicago Style citaatYang, Yang, et al. The Syndecan-1 Heparan Sulfate Proteoglycan Is a Viable Target for Myeloma Therapy. American Society of Hematology, 2007.
MLA citatieYang, Yang, et al. The Syndecan-1 Heparan Sulfate Proteoglycan Is a Viable Target for Myeloma Therapy. American Society of Hematology, 2007.
Let op: Deze citaties zijn niet altijd 100% accuraat.